4.6900
+0.4300
+(10.09%)
At close: April 11 at 4:00:01 PM EDT
4.5100
-0.18
(-3.84%)
After hours: April 11 at 5:59:44 PM EDT
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
66,591
67,635
79,204
86,160
97,074
Operating Expense
176,939
189,326
216,411
210,004
206,647
Operating Income
-110,348
-121,691
-137,207
-123,844
-109,573
Net Non Operating Interest Income Expense
3,810
3,830
6,212
1,573
2,021
Other Income Expense
--
73
--
83
-27
Pretax Income
-106,465
-117,788
-130,995
-122,188
-107,579
Tax Provision
-1,537
-1,743
2,821
-433
-28,583
Net Income Common Stockholders
-104,928
-116,045
-133,816
-121,755
-78,996
Diluted NI Available to Com Stockholders
-104,928
-116,045
-133,816
-121,755
-78,996
Basic EPS
-4.95
-5.48
-6.38
-5.91
-3.92
Diluted EPS
-4.95
-5.48
-6.38
-5.91
-3.92
Basic Average Shares
21,194.5000
21,157
20,969
20,603
20,171
Diluted Average Shares
21,194.5000
21,157
20,969
20,603
20,171
Total Operating Income as Reported
-110,348
-121,691
-137,207
-123,844
-109,573
Total Expenses
176,939
189,326
216,411
210,004
206,647
Net Income from Continuing & Discontinued Operation
-104,928
-116,045
-133,816
-121,755
-78,996
Normalized Income
-104,999.9461
-116,116.9050
-133,816
-121,837.6680
-78,996
Interest Income
13,271
14,770
11,360
1,573
2,021
Interest Expense
9,461
10,940
5,148
--
--
Net Interest Income
3,810
3,830
6,212
1,573
2,021
EBIT
-97,004
-106,848
-125,847
-122,188
-107,579
EBITDA
-94,421
-104,512
-123,476
-119,215
-104,245
Reconciled Depreciation
2,583
2,336
2,371
2,973
3,334
Net Income from Continuing Operation Net Minority Interest
-104,928
-116,045
-133,816
-121,755
-78,996
Total Unusual Items Excluding Goodwill
73
73
--
83
-27
Total Unusual Items
73
73
--
83
-27
Normalized EBITDA
-94,494
-104,585
-123,476
-119,298
-104,245
Tax Rate for Calcs
0
0
0.0002
0
0.0003
Tax Effect of Unusual Items
1.0539
1.0950
--
0.3320
--
9/30/2021 - 3/21/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ITOS iTeos Therapeutics, Inc.
5.65
+9.07%
XNCR Xencor, Inc.
8.54
+7.83%
DNTH Dianthus Therapeutics, Inc.
17.61
+12.88%
CGEM Cullinan Therapeutics, Inc.
7.71
+1.72%
KALV KalVista Pharmaceuticals, Inc.
11.49
+9.01%
MGNX MacroGenics, Inc.
1.2900
+3.20%
AVTE Aerovate Therapeutics, Inc.
2.6600
+3.10%
PMVP PMV Pharmaceuticals, Inc.
0.8720
+0.23%
ATXS Astria Therapeutics, Inc.
4.0400
-0.49%
ANAB AnaptysBio, Inc.
17.17
+5.73%